🇺🇸 FDA
Patent

US 8932818

Screening assays for compounds that modulate programmed ribosomal frameshifting

granted A61KA61K31/4035A61P

Quick answer

US patent 8932818 (Screening assays for compounds that modulate programmed ribosomal frameshifting) held by PTC THERAPEUTICS, INC. expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PTC THERAPEUTICS, INC.
Grant date
Tue Jan 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/4035, A61P, A61P31/12, A61P43/00